Literature DB >> 21514811

Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias.

Kizuku Watanabe1, Tomohiro Handa, Kiminobu Tanizawa, Yuji Hosono, Yoshio Taguchi, Satoshi Noma, Yoichiro Kobashi, Takeshi Kubo, Kensaku Aihara, Kazuo Chin, Sonoko Nagai, Tsuneyo Mimori, Michiaki Mishima.   

Abstract

OBJECTIVES: Antisynthetase syndrome (ASS) is characterized by autoantibodies to aminoacyl-tRNA synthetases (anti-synthetase) and it is frequently associated with interstitial lung disease. The purpose of this study was to elucidate the prevalence and characteristics of the anti-synthetase positive subpopulation among idiopathic interstitial pneumonias (IIPs) and to clarify the importance of screening for these antibodies.
METHODS: A retrospective study was performed in 198 consecutive cases with IIPs. Screening for six anti-synthetase antibodies was performed in all cases. Clinical profiles of all cases were compared with reference to the presence of anti-synthetase. High-resolution computed tomography (HRCT) findings of anti-synthetase positive cases were also analyzed.
RESULTS: 13 cases (6.6%) were positive for anti-synthetase. Anti-EJ was most prevalent, followed by anti-PL-12. Onset ages of anti-synthetase positive cases were younger than those of anti-synthetase negative cases. Extrapulmonary features of ASS were absent in 6 anti-synthetase positive cases (46.2%). Histologically, among 5 UIP with lymphoid follicles and 11 NSIP cases, the prevalence of anti-synthetase positive cases was 8/16 (50%). On HRCT, ground glass opacity and traction bronchiectasis were the major findings in anti-synthetase positive cases, while honeycombing was absent.
CONCLUSIONS: Anti-synthetase positive cases were not rare among IIPs. Anti-synthetase should be screened for in IIPs, especially in pathological NSIP or UIP with lymphoid follicles. These patients should be screened for anti-synthetase even if no suggestive extrapulmonary manifestation exists.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21514811     DOI: 10.1016/j.rmed.2011.03.022

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  30 in total

1.  Interstitial lung disease associated with anti-citrullinated peptide/protein antibody-positive anti-synthetase syndrome.

Authors:  Hideaki Yamakawa; Eri Hagiwara; Tae Iwasawa; Ryota Otoshi; Erina Tabata; Satoshi Ikeda; Ryo Okuda; Tomohisa Baba; Shinichiro Iso; Koji Okudela; Tamiko Takemura; Shinji Sato; Takashi Ogura
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

2.  Interstitial lung disease in a child with antisynthetase syndrome.

Authors:  Don Hayes; Peter B Baker; Heidi M Mansour; Mark E Peeples; Kathleen K Nicol
Journal:  Lung       Date:  2013-05-08       Impact factor: 2.584

3.  Screening for Myositis Antibodies in Idiopathic Interstitial Lung Disease.

Authors:  Lee Fidler; Irena Doubelt; Sonja Kandel; Jolene H Fisher; Shikha Mittoo; Shane Shapera
Journal:  Lung       Date:  2019-03-05       Impact factor: 2.584

Review 4.  Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Authors:  Tsuneyo Mimori; Ran Nakashima; Yuji Hosono
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

5.  Heterogeneous clinical spectrum of interstitial lung disease in patients with anti-EJ anti-synthetase syndrome: a case series.

Authors:  Margherita Giannini; Antonella Notarnicola; Maryam Dastmalchi; Ingrid E Lundberg; Giuseppe Lopalco; Florenzo Iannone
Journal:  Clin Rheumatol       Date:  2016-04-11       Impact factor: 2.980

Review 6.  Clinical heterogeneity and outcomes of antisynthetase syndrome.

Authors:  Baptiste Hervier; Olivier Benveniste
Journal:  Curr Rheumatol Rep       Date:  2013-08       Impact factor: 4.592

7.  The Diagnosis and Treatment of Antisynthetase Syndrome.

Authors:  Leah J Witt; James J Curran; Mary E Strek
Journal:  Clin Pulm Med       Date:  2016-09

Review 8.  Autoantibodies in myositis.

Authors:  Neil J McHugh; Sarah L Tansley
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

Review 9.  The evolving spectrum of polymyositis and dermatomyositis--moving towards clinicoserological syndromes: a critical review.

Authors:  Sarah Tansley; Harsha Gunawardena
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 10.  The Clinical Features of Myositis-Associated Autoantibodies: a Review.

Authors:  Harsha Gunawardena
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.